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16/j.arabAbstract A new liquid chromatography mass spectrometry method with electrospray ionization
was developed for the estimation of Ondansetron in human plasma. Sample preparation was carried
out by solid-phase extraction that enabled direct injection into the LC–MS/MS system. Ondanse-
tron and an internal standard (ISTD), Ramosetron, were separated by using a Gemini NX C18 ana-
lytical column (100 · 4.6 mm i.d., particle size 5 lm) with isocratic elution. The mobile phase was
composed of a mixture of ammonium formate buffer (pH 3.0; 2 mM) and acetonitrile (30:70, v/
v), pumped at a ﬂow rate of 0.5 mL/min. Quantitation of the analyte was performed with multiple
ion monitoring (MRM) in positive ionization mode using electrospray ionization interface. The ion
transitions recorded were m/z 294.3/170.0 for Ondansetron and m/z 280.3/121.3 for ISTD. The
method was validated over a wide dynamic concentration range of 1.00–100.00 ng/mL
(rP 0.9996). The lower limit of quantitation (LLOQ) was 1.00 ng/mL. The extraction recovery
was above 81.50% for analyte and above 85.33% for ISTD. A run time of less than 3.0 min for each
sample made it possible to analyze a large number of human plasma samples per day. The proposed
method was successfully applied for determination of Ondansetron in bioequivalence study of 4 or
8 mg Ondansetron tablet.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.24637618.
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Ondansetron, (RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-
methyl]-1,2,3,9-Tetrahydro-4H-carbazol-4-one monohydro-
chloride, is a selective serotonin 5-HT3 receptor antagonist
with antiemetic activity (Raza et al., 2007; Alam et al., 2012;ier B.V. All rights reserved.
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2 G. Ninama et al.Mujtaba et al., 2013). It is used in the management of nausea
and vomiting induced by cytotoxic chemotherapy and radio-
therapy. The antiemetic activity of the drug is brought about
through the inhibition of 5-HT3 receptors present both cen-
trally (medullary chemoreceptor zone) and peripherally (GI
tract). This inhibition of 5-HT3 receptors in turn inhibits the
visceral afferent stimulation of the vomiting center, likely
indirectly at the level of the area postrema, as well as through
direct inhibition of serotonin activity within the area postrema
and the chemoreceptor trigger zone.
Literature survey revealed that Fluorescence polarization
immunoassay, radioimmunoassay, HPTLC, capillary zone
electrophoresis, Liquid chromatography–mass spectrometric
(LC–MS/MS) method and ion-pair chromatography methods
have been used to quantify Ondansetron in pharmaceutical
dosage forms and biological ﬂuids (Raza et al., 2007; Varvara
et al., 2009; Alam et al., 2012; Mujtaba et al., 2013). Also, there
have been reports on gradient HPLC methods with UV detec-
tion (Dedania et al., 2009; Shashela et al., 2009). However,
these reported methods utilize laborious and time-consuming
sample preparation procedure, gradient development, having
lower sensitivity and comparatively longer run time
(Koufopantelisa et al., 2009; Alvarez et al., 2011) which limit
their application. In spite, of different approaches available
for quatitation of ondansetron, it would be of particular
interest to develop a rapid, accurate, precise and sensitive
method to overcome the drawbacks of reported methods.
In view of the above facts, authors attempted the develop-
ment and validation of a new, rapid, isocratic, accurate, precise
and sensitive, hyphenated LC–MS/MS method for the estima-
tion of Ondansetron in human plasma. The assay was based on
200 lL human plasma samples, following solid-phase extrac-
tion that enabled direct injection into the LC–MS/MS system
using positive electrospray ionization. The method was
successfully applied for the determination of Ondansetron in
bioequivalence study of 4 or 8 mg Ondansetron tablet in
Indian males in fasting condition.2. Experimental
2.1. Materials
2.1.1. Reference/working standards
Ondanseron hydrochloride (purity, 99.00%) and Ramosetron
hydrochloride (purity, 99.58%) were provided as gratis
samples by Cadila Pharmaceuticals Limited (Ankleshwar,
Gujarat, India) and Changzhou Wujin Pharmaceutical Chem-
ical Co. Ltd (China), respectively.
2.1.2. Chemicals and reagents
Acetonitrile and Methanol were of HPLC grade and were pur-
chased from Merck Inc. (USA). Formic acid and Ammonium
formate were of AR grade and were purchased from Merck
Inc. (USA). HPLC grade water was obtained in-house using
a Millipore Milli-Q Gradient Water Puriﬁcation System
(USA).
2.1.3. Human plasma
Human plasma was obtained from the Cadila Pharmaceuticals
Ltd. (CRO, dholka, India). Dipotassium ethylene diaminePlease cite this article in press as: Ninama, G. et al., Solid phase extraction
ionization for the determination of Ondansetron in human plasma: Deve
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.12.004tetra-actetic acid (K2EDTA) was used as an anticoagulant.
Haemolyzed, lipemic and Sodium-Heparin containing human
plasma required for selectivity/speciﬁcity experiment were also
obtained from Cadila Pharmaceuticals Ltd. (CRO, Dholka,
India).
2.2. Equipment and apparatus
Analysis was performed on a LC–MS/MS system consisting of
an API 4000 triple quadrupole mass spectrometer (Applied
Biosystems/MDS SCIEX, USA) equipped with an electro-
spray ionization interface (Turbo Ion Spray) and a LC-
20AD (Shimadzu, Kyoto, Japan) LC system accompanied
with an autosampler SIL-HTC (Shimadzu, Kyoto, Japan). A
Nitrox-N2 model UHPLC–MS12E nitrogen generator (Gates-
head, England) was used to provide highly pure nitrogen that
was utilized as sheath and nebulizing gas. Data acquisition and
analysis were performed using Analyst Software version 1.4.2
(Applied Biosystems, USA). Micropipettes (Eppendorf India
Ltd., India) of different volume capacity like, 2–20, 10–100,
20–200 and 100–1000 lL were used for transfer of sample
and reagents.
2.3. Chromatographic conditions
An analytical method based on solid phase extraction has been
developed for estimation of Ondansetron in human plasma
using Ramosetron as an internal standard (ISTD). Lichrosep
Sequence Cartridge (30 mg – 1 mL) was used for solid phase
extraction. Analytes were exracted from human plasma using
Positive Pressure Processor Extraction Manifold (Ezypress
48, Orochem India Pvt. Ltd. India). Analytes were separated
using an analytical column, Gemini NX C18 (Phenomenex,
USA), (100 mm length; 4.6 mm internal diameter; particle size
5 lm). Mobile phase was composed of ammonium formate
buffer (pH 3.0 adjusted with formic acid; 2 mM) and acetoni-
trile (30:70, v/v). The aliquots of resulting samples were ana-
lyzed by combining liquid chromatography and tandem mass
spectrometry (LC–MS/MS) with positive ion Electro spray
ionization using multiple reaction monitoring (MRM). The
elution was achieved isocratically at a ﬂow rate of 0.5 mL/
min with injection volume of 5 lL. The run time was as low
as 3.0 min.
2.4. Mass spectrometric conditions
The analytes were detected by an API 4000 triple quadrupole
mass spectrometer (Applied Biosystems/MDS SCIEX, USA)
equipped with an electrospray ionization interface (Turbo
Ion Spray). The Analyst Software version 1.4.2 (Applied
Biosystems) was used for system control, data acquisition
and quantiﬁcation. The ESI source was working in the positive
ionization mode, and an ion-spray voltage of +5500 V was
applied. The capillary temperature was set to 400 C. The
system was tuned using a continuous 5 lL/min infusion of
an Ondansetron (200 ng/mL) solution in acetonitrile. The sig-
nal was optimized on the total ion current in MS mode. The
protonated precursor molecular ions [MH]+ of Ondansetron
(m/z 294.3) and ISTD (m/z 280.3) were trapped with a mass
resolution of 1.0 amu and fragmented by collision induced
dissociation with an activation time of 200 ms; collision energyliquid chromatography mass spectrometry method with electrospray
lopment and validation consideration. Arabian Journal of Chemistry
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tain gas pressure, 30 psi; nebulizer gas pressure 40 psi; heater
gas pressure 60 psi. The daughter ions resulting from these
fragmentations were monitored in multiple reaction monitor-
ing (MRM). Ondansetron was identiﬁed by the presence of
daughters’ ions at m/z 170.0 and ISTD was identiﬁed by the
presence of daughter ions at m/z 121.3.
2.5. Preparation of calibration curve standards (CC) and
quality control (QC) samples
Ondansetron stock solution (1000.00 ng/mL) and intermediate
stock solution (10.00 ng/mL) for CC samples were prepared in
methanol–water (50:50, v/v). ISTD stock solution (1000.00 ng/
mL) and intermediate ISTD dilution (500.00 ng/mL) were
prepared in methanol–water (50:50, v/v). CC samples were
prepared by spiking respective intermediate stock solutions
in blank human plasma at concentrations of 1, 2, 6, 15, 30,
50, 80 and 100 ng/mL. CC samples were prepared from a
screened and pooled K2EDTA containing human blank plas-
ma. Ondansetron stock solution for QC was prepared sepa-
rately and QC plasma samples were prepared at 1, 3, 14, 35,
and 70 ng/mL (LLOQ QC, LQC, MQC2, MQC1 and HQC,
repectively) in the same manner as for plasma standard. QC
samples were prepared from different matrix pools on each
day of analysis. Zero standard was prepared by diluting
20 lL of ISTD dilution (500 ng/mL) with 200 lL of screened
plasma. All prepared plasma samples were stored at tempera-
ture of 20 ± 5 C or 70 ± 5 C in deep freezer (Sanyo,
Germany) and all prepared stock solutions were stored at
2–8 C in refrigerator (Vestfrost, UK).2.6. Preparation of working solutions for short term/long term
stock solution stability
Working spiking solutions for short term/long term stock solu-
tion stability were prepared by diluting drug intermediate
stock solution (10.000 lg/mL) with diluent (methanol–water,
60:40, v/v).2.7. Sample preparation
2.7.1. Extracted sample preparation
The required number of samples from the deep freezer were re-
trieved and thawed in water bath maintained at room temper-
ature and the tubes were vortexed. 0.2 mL of sample was
transferred into a pre-labeled tube. 20 lL of ISTD dilution
(0.500 lg/mL) was added to all the samples except plasma
blank (STD BL) and vortexed. 20 lL diluent (methanol–water,
60:40, v/v) was added in STD BL sample and vortex mixed.
The conditioning of cartridges (Lichrosep Sequence 30 mg –
1 mL) was carried out with 1 mL methanol followed by
1 mL Milli-Q water. CC standard or QC samples were loaded
in cartridge respectively. Cartridges were washed with 1 mL
Milli-Q water twice. Cartridges were dried at maximum pres-
sure in Positive Pressure Processor for 2 min. All the samples
were eluted with 1 mL mobile phase. About 0.6 mL of eluted
solution was transferred in pre-labeled autosampler vials and
were arranged in the auto-sampler and injected in LC–MS/
MS system.Please cite this article in press as: Ninama, G. et al., Solid phase extraction
ionization for the determination of Ondansetron in human plasma: Deve
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.12.0042.7.2. Aqueous sample preparation
Aqueous samples were prepared by transferring 2440 lL of
mobile phase in prelabelled tubes. 10 lL of respective spiking
solutions was added in prelabelled tubes and was vortexed.
50 lL of ISTD dilution (0.500 lg/mL) was added and
vortex-mixed. The samples were transferred into prelabelled
auto-sampler vials and injected in LC–MS/MS system.
2.8. Validation
The method was validated for accuracy, precision, sensitivity/
speciﬁcity, calibration curve range, and reproducibility accord-
ing to the USFDA guideline for validation of bioanalytical
methods (Guidance for the industry: Bioanalytical method
validation, 2001).
2.8.1. Calibration curve and linearity
An eight-point calibration curve was constructed by plotting
peak area ratio (y) of Ondansetron to the ISTD versus Ondan-
setron concentrations (x). Analysis of CC samples at each
concentration was performed in duplicate. Results for blank
samples were not used as part of the calibration curve. Slope,
intercept and correlation coefﬁcient were calculated as regres-
sion parameters by weighted (1/x2) linear regression.
2.8.2. Intra-day and inter-day precision and accuracy
The following samples plasma blank, zero standard, calibra-
tion standards, QC samples (six replicates) were injected in a
sequence for a precision and accuracy batch. Samples were
processed and the concentrations of quality control samples
were calculated by quantifying them against calibration stan-
dards. One precision and accuracy batch on single day was
generated for intra-day precision and accuracy. Three preci-
sion and accuracy batches were generated on different days
for inter-day precision and accuracy.
2.8.3. Speciﬁcity
Samples of six normal matrices, one lipemic and one haemo-
lyzed matrix were obtained. The lowest calibration standard
sample and blank sample in each matrix were prepared. The
interference in each blank sample was checked by comparing
the area response obtained in the lowest calibration sample
of that matrix using an established procedure for analysis. %
interference was calculated.
2.8.4. Matrix effect
Three samples each of LQC and HQC were prepared from
each of six blank plasmas. These QC samples along with cali-
bration standards prepared from one blank matrix were in-
jected and these QC samples were quantiﬁed against the
calibration curve to calculate concentration.
2.8.5. Recovery
The recovery of Ondansetron and internal standard (Ramose-
tron) by comparing the bioanalytical results for extracted QC
samples with aqueous solutions equivalent to 100% recovery
of LQC, MQC and HQC was evaluated. Six samples each of
LQC, MQC and HQC (six replicates) were processed. The
comparison samples in aqueous medium at low, medium and
high quality control level were prepared which constituteliquid chromatography mass spectrometry method with electrospray
lopment and validation consideration. Arabian Journal of Chemistry
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of extracted samples. These comparison samples were analyzed
along with extracted QC samples and% mean recovery was
calculated by comparing area obtained in extracted samples
with that of aqueous samples. The % mean recovery of inter-
nal standard was calculated at all levels.
2.8.6. Dilution integrity
Aqueous solution having concentration approximately three
times of ULOQ was prepared. Aqueous sample was spiked
in blank plasma. Then spiked matrix was diluted ﬁve and tenFigure 1 Representative chromatograms of (A) human plasma b
Please cite this article in press as: Ninama, G. et al., Solid phase extraction
ionization for the determination of Ondansetron in human plasma: Deve
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.12.004times with blank plasma. Six samples each from ﬁve times
and ten times diluted matrix were processed and injected along
with calibration standards and these diluted QC smaples were
quantiﬁed against calibration curve to calculate concentration.
2.8.7. Stability
The short term stability of Ondansetron and ISTD in stock
solutions was carried out for 6 h from the time of preparation.
The long term stability of Ondansetron and ISTD in stock
solutions was carried out for 6 days from the time of prepara-
tion. The % mean stability was calculated. Stability oflank (B) Zero standard (C) Ondansetron and (D) Ramosetron.
liquid chromatography mass spectrometry method with electrospray
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Table 1 Calibration curve parameters.
P&A batch ID Slope Intercept r
P&A I 0.119 0.015 0.9996
P&A III 0.120 0.003 0.9990
P&A IV 0.120 0.002 0.9992
Solid phase extraction liquid chromatography mass spectrometry method 5Ondansetron in human plasma was carried out at low and high
quality control levels (six replicates). Freeze–thaw stability was
carried out using stability samples at 70 C and ﬁve freeze–
thaw cycles. Bench top stability was carried out by keeping sta-
bility samples on bench at room temperature for 13 h 20 min.
Wet extract stability was carried out by processing stability
samples and stored in a wet extract form at 5 C in a refriger-
ator for 24 h. Autosampler stability was carried out after sta-
bility samples were stored in auto sampler for 52 h at 5 C.
The % change was calculated.
3. Results and discussion
3.1. Optimized chromatographic conditions
To separate the Ondansetron (analyte) and Ramosetron
(ISTD) three types of stationary phase columns were tried
including Hipurity C18 (50 · 4.6 mm, 5 lm), Phenomenex
C18 (100 · 4.6 mm, 5 lm) and Gemini NX C18
(100 · 4.6 mm, 5 lm). Poor chromatography in terms of reso-
lution and symmetric factor for Ondansetron was observed on
Hipurity C18 (100 · 4.6 mm, 5 lm) and Phenomenex C18
(100 · 4.6 mm, 5 lm) columns although various percentages
of acetonitrile and different pH of buffers were tested. Ondan-
setron was extracted using different types of extraction meth-
ods like precipitation and solid phase extraction from the
spiked plasma samples. Response of blank plasma was ob-
served in the precipitation extraction method. Then solid phase
extraction was carried out for extraction of Ondansetron using
Lichrosep Sequence Cartridge (30 mg – 1 mL). Interference in
blank plasma response was resolved in the solid phase extrac-
tion method. In order to make the mobile phase suitable for
LC–MS/MS, the probability of using higher proportion of or-
ganic component of acetonitrile was attempted. After achiev-
ing good chromatography in Gemini NX C18 (100 · 4.6 mm,
5 lm), the saturation of ISTD response was observed but it
was resolved by diluting the ISTD dilution to appropriate
concentration. Representative chromatograms of (A) humanFigure 2 Representative ﬁgure of the
Please cite this article in press as: Ninama, G. et al., Solid phase extraction
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(2013), http://dx.doi.org/10.1016/j.arabjc.2013.12.004plasma blank (B) Zero Standard (C) Ondansetron and (D)
Ramosetron are shown in Fig. 1.
Finally, all the subsequent plasma samples thus run with
the mobile phase consisted of ammonium formate buffer
(pH 3.0, adjusted with formic acid; 2 mM) – acetonitrile
(30:70, v/v) and were separated using an analytical column,
Gemini NX C18 (100 · 4.6 mm, 5 lm). The elution was
achieved isocratically at a ﬂow rate of 0.5 mL/min with injec-
tion volume of 5 lL.
3.2. Method validation
The calibration curve (Fig. 2) was linear over the concentra-
tion range of 1.00–100.00 ng/mL of Ondansetron in human
plasma with a regression coefﬁcient of determination
(r)P 0.9990. The average slope and intercept of regression
equations were 0.120 and 0.003, respectively. The calibration
curve parameters are summarized in Table 1. Linearity was
found to be quite satisfactory and reproducible with time.
The precision and accuracy data for QCs are summarized in
Table 2. For QC samples at 1.00 ng/mL (LLOQ), intra-assay
mean accuracy and precision values were 90.73% and
4.18%, respectively, while above LLOQ they were 96.53–
104.25% and 63.00%. Inter-assay mean accuracy and preci-
sion at LLOQ were 98.61% and 7.76%, respectively and above
LLOQ, 95.93–100.11% and 64.02%, respectively.
The speciﬁcity of the analytical method was investigated by
analyzing six individual human blank plasma samples. The
acceptance criteria for Ondansetron were mean interference
per batch 620% of signal at LLOQ, and that for ISTDcalibration curve of Ondansetron.
liquid chromatography mass spectrometry method with electrospray
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Table 5 Stability of drug and ISTD stock solution.
Stability Nominal area observed Mean area observed % Mean stability
Short term stock solution stability
Ondansetron 3,925,802 4,029,915 102.650
ISTD 367,649 399,512 108.670
Long term stock solution stability
Ondansetron 9,685,504 9,641,251 99.540
ISTD 682,654 681,732 99.860
Table 2 Intra-day and inter-day precision and accuracy.
QC sample ID HQC MQC1 MQC2 LQC LLOQ QC
Nominal concentration (ng/mL) 70.000 35.000 14.000 3.000 1.000
Back calculated concentration (ng/mL)
Intra-day (n = 6)
Mean 72.897 35.710 14.595 2.896 0.907
SD 2.186 0.593 0.124 0.056 0.038
% CV 3.000 1.660 0.850 1.940 4.180
% Mean accuracy 104.140 102.030 104.250 96.530 90.730
Inter-day (n = 18)
Mean 69.746 34.122 14.016 2.878 0.986
SD 2.800 1.273 0.502 0.083 0.077
% CV 4.020 3.730 3.580 2.890 7.760
% Mean accuracy 99.640 97.490 100.110 95.930 98.611
Table 3 Recovery study.
Replicate
No.
HQC MQC1 MQC2 LQC
Extracted
peak area
Un-
extracted
peak area
Extracted
peak area
Un-
extracted
peak area
Extracted
peak area
Un-
extracted
peak area
Extracted
peak area
Un-
extracted
peak area
Mean 2,039,854 2,454,094 1,002,701 1,262,515 404,234 495,887 88,293 107,908
SD 15,191 66,286 61,745 6429 3564 3818 926 2621
% CV 0.740 2.700 0.620 0.510 0.880 0.770 1.050 2.430
% Mean
recovery
83.120 79.420 81.520 81.820
% Overall
recovery
81.500
Table 4 Dilution Integrity study.
Replicate No. DI spiked standard concentration (ng/mL)
DI 1/2 sample (ng/mL) DI 1/10 sample (ng/mL)
85.000 170.000 17.000 170.000
Without DF With DF Without DF With DF
Mean 91.251 182.501 17.818 178.177
SD 04.647 09.294 00.703 07.034
% CV 05.090 05.090 03.950 03.950
% Mean accuracy 107.350 107.350 104.810 104.810
6 G. Ninama et al.was mean interference per batch 65% of signal at working
concentration. No interference peak was detected for
Ondansetron or ISTD.Please cite this article in press as: Ninama, G. et al., Solid phase extraction
ionization for the determination of Ondansetron in human plasma: Deve
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.12.004Three samples of each LLOQ from each seven plasma lots
were prepared and injected along with calibration standards
prepared from one blank plasma. The % accuracy of LLOQliquid chromatography mass spectrometry method with electrospray
lopment and validation consideration. Arabian Journal of Chemistry
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found to be 91.88%, which is within the range of 80.00–
120.00% and precision (% CV) was found to be 3.42% which
is acceptance criteria of 20.00%. All of the matrix lots were
found to be within the acceptance criteria (at least 80% of
samples).
The extraction recovery was assessed by comparison of the
responses obtained from analysis of extracted spiked human
samples and unextracted samples. The absolute extraction
recoveries for Ondansetron and ISTD were 81.50% and
85.33%, respectively (Table 3).
The% mean accuracy of the DI 1/2 samples was found to
be 107.350% with dilution factor of 2. The % mean accuracy
of the DI 1/10 samples was found to be 104.810% with dilu-
tion factor of 10% CV of DI 1/2 samples and DI 1/10 samples
was found to be 5.090% and 3.950% (Table 4).
% Mean short term stock solution stability for drug and
ISTD was found to be 102.650% and 108.670%, respectively.
The short term stability of Ondansetron and ISTD in stock
solutions was found to be 7 h 10 min at ambient temperature
for both. The % mean long term stock solution stability for
drug and ISTD was found to be 99.540% and 99.860%,
respectively. The long term stability of Ondansetron and ISTD
in stock solutions was found to be 06 days at 5 ± 3 C. The %
mean stability for freeze–thaw stability for drug and ISTD was
found to be 99.540% and 99.860%, respectively. Freeze–thaw
stability samples were found to be stable for ﬁve freeze–thaw
cycles at 70 ± 5 C. Bench top stability was found to be
13 h 20 min at ambient temperature. Wet extract stability
was found to be 43 h 30 min at 5 ± 3 C. Autosampler stabil-
ity was found to be 56 h 46 min at 5 ± 3 C (Table 5).
4. Conclusion
The developed rapid Hyphenated Liquid Chromatography-
Tandem Mass Spectrometry method using API-4000 massPlease cite this article in press as: Ninama, G. et al., Solid phase extraction
ionization for the determination of Ondansetron in human plasma: Deve
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.12.004spectrometer substantially improves sensitivity, accuracy and
precision for the quantitation of Ondansetron in human plas-
ma at a concentration range of 1.00–100.00 ng/mL. The
proposed method enabled the reliable determination of
Ondansetron in bioequivalence study of 4 or 8 mg Ondanse-
tron tablet. Selectivity and sensitivity were sufﬁcient for detect-
ing and quantifying Ondansetron in human plasma. These
features coupled with a short run time at 3.0 min compared
to reported methods which allow high sample throughput with
almost 500 samples per day. The proposed method enabled the
reliable determination of Ondansetron in bioequivalence study
of 4 or 8 mg Ondansetron tablet.
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